Jeltsch, Michael
https://orcid.org/0000-0003-2890-7790 Description of research
Finnish-German biochemist, high school diploma from Gymnasium An der Stenner (Iserlohn, Germany), undergraduate studies at the University of Hamburg, PhD from the University of Helsinki, Finland in 2003 with Kari Alitalo: discovery of the first growth factors for lymphatic vessels: VEGF-C and VEGF-D. Since 2020 associate professor at the Faculty of Pharmacy, University of Helsinki. Experience in three biotech startups with several patents and three drugs in clinical trials: OPT-302/sozinibercept (developer, phase III), VGX-100 and Lymfactin (co-developer, up to phase I and II, respectively). Currently working on novel and sustainable protein expression systems.Affiliations
University of Helsinki
Unit
Translational Cancer Biology Program/Individual Drug Therapy Research Program
Source: ORCID
Title
Group leader 2013 - 2020
Unit
Drug Research Program
Source: ORCID
Title
Associate Professor in Pharmaceutical Protein Drug Research 2020
Unit
Molecular/Cancer Biology Laboratory
Source: ORCID
Title
Postdoctoral Fellow 2003 - 2013
Unit
Molecular/Cancer Biology Laboratory
Source: ORCID
Title
Graduate Student 1996 - 2002
Wihuri Research Institute
Source: ORCID
Title
Postdoctoral Fellow 2013 - 2013
Vegenics Ltd/Circadian Technologies via Licentia Oy (now Opthea)
Source: ORCID
Title
Contract Researcher 2007 - 2011
Helsinki University Licencing Ltd./Licentia Ltd.
Source: ORCID
Title
Contract Researcher 1999 - 2005
Heinrich-Pette-Institut Leibniz-Institut fur Experimentelle Virologie
Unit
Group Hans Will
Source: ORCID
Title
Research Assistant 1994 - 1995
Lymphatix Oy (acquired by Ark Therapeutics)
Source: ORCID
Title
Researcher 2006 - 2007
Education
Degrees
MSc 1994 - 1997 / University of Helsinki
Baccalaureate 1980 - 1989 / Gymnasium An der Stenner
PhD 1997 - 2002 / University of Helsinki
BSc/"Vordiplom" 1990 - 1994 / University of Hamburg
Publications (55)
The Relationship between the Secondary Vascular System and the Lymphatic Vascular System in Fish
2023
Bioactive VEGF-C from E. coli
2022
Expansion and collapse of VEGF diversity in major clades of the animal kingdom
2022
Granted funding (1)
Development of a biotherapeutical to counter cancer “resistance” to presently used anti- angiogenic drugsResearch Council of Finland2013 - 2018